{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:48:42Z","timestamp":1788900522517,"version":"build-2803163510"},"reference-count":41,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,14]]},"DOI":"10.18632\/oncotarget.9027","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T03:59:46Z","timestamp":1461729586000},"page":"35818-35831","source":"Crossref","is-referenced-by-count":54,"title":["Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer"],"prefix":"10.18632","volume":"7","author":[{"given":"Yun","family":"Xia","sequence":"first","affiliation":[{"name":"Department of General Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Department of Pathology and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiang-Ching","family":"Huang","sequence":"additional","affiliation":[{"name":"Joseph J. Zilber School of Public Health, University of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dittmar","sequence":"additional","affiliation":[{"name":"Department of Pathology and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pathology and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Kohli","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,4,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Cooney","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Crawford","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Investigators","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000019546","article-title":"Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center","volume":"33","author":"Sylvester","year":"1998","journal-title":"Eur Urol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Thompson","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"7","first-page":"1491","article-title":"Prostate Cancer Trialists' Collaborative Group","volume":"355","author":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","year":"2000","journal-title":"Lancet"},{"key":"8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"Cheng","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Sims","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"Shen","year":"2010","journal-title":"The Lancet"},{"key":"11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ng","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Saad","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"13","first-page":"19","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis","volume":"16","author":"Botteman","year":"2012","journal-title":"Journal of medical economics"},{"key":"14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Goessl","year":"2011","journal-title":"Lancet"},{"key":"15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: monitoring cancer-genetics in the blood","volume":"10","author":"Bardelli","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4065\/mcp.2009.0442","article-title":"New Developments in the Medical Management of Prostate Cancer","volume":"85","author":"Tindall","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"17","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Dearnaley","year":"2009","journal-title":"Journal of clinical oncology"},{"key":"18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Bardelli","year":"2014","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","article-title":"Circulating tumor DNA as a liquid biopsy for cancer","volume":"61","author":"Geigl","year":"2015","journal-title":"Clin Chem"},{"key":"20","doi-asserted-by":"publisher","first-page":"16411","DOI":"10.18632\/oncotarget.3845","article-title":"Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer","volume":"6","author":"Hovey","year":"2015","journal-title":"Oncotarget"},{"key":"21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/302960","article-title":"Genomewide scan for prostate cancer-aggressiveness loci","volume":"67","author":"Catalona","year":"2000","journal-title":"American journal of human genetics"},{"key":"22","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1158\/0008-5472.CAN-07-1297","article-title":"Integrative analysis of genomic aberrations associated with prostate cancer progression","volume":"67","author":"Shah","year":"2007","journal-title":"Cancer research"},{"key":"23","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/carcin\/bgq081","article-title":"Comprehensive analysis of the cytokine-rich chromosome 5q31. 1 region suggests a role for IL-4 gene variants in prostate cancer risk","volume":"31","author":"Australian Prostate Cancer","year":"2010","journal-title":"Carcinogenesis"},{"key":"24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.10289","article-title":"RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer","volume":"39","author":"Visakorpi","year":"2004","journal-title":"Genes, Chromosomes and Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/ng.406","article-title":"The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling","volume":"41","author":"Niittym\u00e4ki","year":"2009","journal-title":"Nature genetics"},{"key":"26","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ijc.21976","article-title":"Genetic aberrations in prostate cancer by microarray analysis","volume":"119","author":"Visakorpi","year":"2006","journal-title":"International journal of cancer"},{"key":"27","first-page":"2","article-title":"NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states","volume":"29","author":"Costa","year":"2008","journal-title":"Carcinogenesis"},{"key":"28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jcb.22451","article-title":"Down-regulation of Notch -1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-B signaling pathways","volume":"109","author":"Sarkar","year":"2010","journal-title":"J Cell Biochem"},{"key":"29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1078-0432.CCR-08-1631","article-title":"Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator","volume":"15","author":"Mukhtar","year":"2009","journal-title":"Clinical cancer research"},{"key":"30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/clinchem\/46.8.1078","article-title":"Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism","volume":"46","author":"Lichtenstein","year":"2000","journal-title":"Clin Chem"},{"key":"31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1749-6632.2001.tb03892.x","article-title":"Circulating nucleic acids and apoptosis","volume":"945","author":"Umansky","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"key":"32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrclinonc.2013.80","article-title":"Circulating tumour cells and cell-free DNA as tools for managing breast cancer","volume":"10","author":"Seoane","year":"2013","journal-title":"Nature reviews Clinical oncology"},{"key":"33","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease","volume":"124","author":"Kahn","year":"2014","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood-2013-02-482984","article-title":"Detection of an NRAS mutation in Erdheim-Chester disease","volume":"122","author":"Rosenblum","year":"2013","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pbiomolbio.2015.04.006","article-title":"ZNRF3\/RNF43-A direct linkage of extracellular recognition and E3 ligase activity to modulate cell surface signalling","volume":"118","author":"Jones","year":"2015","journal-title":"Progress in biophysics and molecular biology"},{"key":"36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/CMAR.S57846","article-title":"Emerging role for leucine-rich repeat-containing G-protein-coupled receptors LGR5 and LGR4 in cancer stem cells","volume":"6","author":"Goidts","year":"2014","journal-title":"Cancer management and research"},{"key":"37","article-title":"MYC and metabolism on the path to cancer","author":"Dang","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"38","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Vats","year":"2015","journal-title":"Cell"},{"key":"39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/bmm.15.38","article-title":"Cell-free DNA as a novel marker in cancer therapy","volume":"9","author":"Janku","year":"2015","journal-title":"Biomarkers in medicine"},{"key":"40","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/nar\/gkn556","article-title":"Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms","volume":"36","author":"Wang","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","article-title":"Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer","volume":"67","author":"Lu","year":"2015","journal-title":"Eur Urol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:22:08Z","timestamp":1718497328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,26]]},"references-count":41,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,6,14]]}},"alternative-id":["9027","27127882"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9027","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,26]]}}}